Sterling Capital Management LLC Takes Position in AMAG Pharmaceuticals, Inc. (AMAG)

Sterling Capital Management LLC purchased a new position in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 48,045 shares of the specialty pharmaceutical company’s stock, valued at approximately $961,000. Sterling Capital Management LLC owned approximately 0.14% of AMAG Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of AMAG. FMR LLC lifted its position in shares of AMAG Pharmaceuticals by 49.4% during the second quarter. FMR LLC now owns 1,991,368 shares of the specialty pharmaceutical company’s stock worth $38,832,000 after purchasing an additional 658,100 shares in the last quarter. Macquarie Group Ltd. lifted its position in shares of AMAG Pharmaceuticals by 3,646.1% during the second quarter. Macquarie Group Ltd. now owns 516,956 shares of the specialty pharmaceutical company’s stock worth $10,081,000 after purchasing an additional 503,156 shares in the last quarter. Sei Investments Co. lifted its position in shares of AMAG Pharmaceuticals by 1,695.3% during the second quarter. Sei Investments Co. now owns 506,429 shares of the specialty pharmaceutical company’s stock worth $9,876,000 after purchasing an additional 478,220 shares in the last quarter. Opaleye Management Inc. acquired a new stake in shares of AMAG Pharmaceuticals during the second quarter worth about $8,190,000. Finally, Acadian Asset Management LLC lifted its position in shares of AMAG Pharmaceuticals by 177.8% during the second quarter. Acadian Asset Management LLC now owns 513,013 shares of the specialty pharmaceutical company’s stock worth $10,001,000 after purchasing an additional 328,331 shares in the last quarter.

AMAG stock opened at $17.84 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.72 and a current ratio of 2.86. AMAG Pharmaceuticals, Inc. has a fifty-two week low of $11.95 and a fifty-two week high of $26.10. The company has a market cap of $644.43 million, a P/E ratio of -3.12 and a beta of 0.23.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.88) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($1.11). AMAG Pharmaceuticals had a negative return on equity of 13.65% and a negative net margin of 6.98%. The firm had revenue of $122.20 million for the quarter, compared to analysts’ expectations of $118.23 million. During the same quarter in the previous year, the company posted ($4.31) earnings per share. The firm’s quarterly revenue was down 1.7% on a year-over-year basis. Analysts anticipate that AMAG Pharmaceuticals, Inc. will post -2.85 EPS for the current year.

Several brokerages have recently issued reports on AMAG. Deutsche Bank set a $23.00 price target on shares of AMAG Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, September 20th. Zacks Investment Research cut shares of AMAG Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Friday, October 5th. B. Riley increased their price target on shares of AMAG Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, August 6th. Cantor Fitzgerald set a $18.00 price target on shares of AMAG Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, September 26th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $22.00 price target on shares of AMAG Pharmaceuticals in a research report on Friday, August 3rd. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $21.97.

ILLEGAL ACTIVITY WARNING: “Sterling Capital Management LLC Takes Position in AMAG Pharmaceuticals, Inc. (AMAG)” was first posted by Stock Observer and is the property of of Stock Observer. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2018/11/10/sterling-capital-management-llc-takes-position-in-amag-pharmaceuticals-inc-amag.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Featured Story: Can individual investors take part in an IPO?

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply